Acadian Asset Management
OLMA icon

Acadian Asset Management’s Olema Pharmaceuticals OLMA Stock Holding History

Acadian Asset Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-721
Closed -$10K – 2170
2026
Q1 		$10K Sell
721
-18,367
-96% -$409K ﹤0.01% 1979
2025
Q4 		$477K Buy
+19,088
New +$340K ﹤0.01% 1317
2024
Q2 		– Sell
-103,179
Closed -$1.17M – 1869
2024
Q1 		$1.17M Sell
103,179
-152,746
-60% -$1.97M ﹤0.01% 802
2023
Q4 		$3.59M Sell
255,925
-236,956
-48% -$3.18M 0.01% 536
2023
Q3 		$6.08M Sell
492,881
-86,428
-15% -$881K 0.03% 384
2023
Q2 		$5.23M Buy
579,309
+3,409
+0.6% +$20.6K 0.02% 449
2023
Q1 		$2M Hold
575,900
– – 0.01% 715
2022
Q4 		$1.41M Buy
575,900
+2,923
+0.5% +$8.53K 0.01% 761
2022
Q3 		$1.58M Buy
572,977
+106,811
+23% +$453K 0.01% 695
2022
Q2 		$1.9M Buy
466,166
+351,090
+305% +$1.11M 0.01% 649
2022
Q1 		$489K Buy
115,076
+14,454
+14% +$79.7K ﹤0.01% 1007
2021
Q4 		$940K Buy
+100,622
New +$2.08M ﹤0.01% 850

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Acadian Asset Management's OLMA Position: Q2 2026 in Review

Acadian Asset Management sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 721 shares — an estimated $10K sold.

Acadian Asset Management first reported a position in OLMA in Q4 2021 and held it in 12 quarters. The position peaked at $6.08M in Q3 2023. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Acadian Asset Management reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 721 Olema Pharmaceuticals shares in Q2 2026, an estimated $10K.
  • Acadian Asset Management first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Acadian Asset Management's Olema Pharmaceuticals position peaked at $6.08M in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.